China Cord Blood (NYSE: CO) reported earnings on June 18. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q4), China Cord Blood crushed expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly. GAAP earnings per share dropped.

Gross margins increased, operating margins grew, net margins shrank.

Revenue details
 China Cord Blood tallied revenue of $21.4 million. The one analyst polled by S&P Capital IQ expected to see revenue of $16.7 million on the same basis. GAAP reported sales were 35% higher than the prior-year quarter's $15.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.05. The one earnings estimate compiled by S&P Capital IQ anticipated $0.02 per share. GAAP EPS of $0.05 for Q4 were 17% lower than the prior-year quarter's $0.06 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 79.8%, 320 basis points better than the prior-year quarter. Operating margin was 38.2%, 330 basis points better than the prior-year quarter. Net margin was 17.3%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 On the bottom line, the average EPS estimate is $0.04.

Next year's average estimate for revenue is $98.7 million. The average EPS estimate is $0.26.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 35 members out of 56 rating the stock outperform, and 21 members rating it underperform. Among 18 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), seven give China Cord Blood a green thumbs-up, and 11 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on China Cord Blood is buy, with an average price target of $5.50.

Is China Cord Blood the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.